{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:38:56Z","timestamp":1793709536278,"version":"4.6.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.07.017","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:09:22Z","timestamp":1784128162000},"page":"1751-1766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy of different statin intensities combined with ezetimibe on lipid profile improvement in patients with coronary heart disease: A network meta-analysis"],"prefix":"10.1016","volume":"20","author":[{"given":"Qingsheng","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6996-6167","authenticated-orcid":false,"given":"Peng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jacl.2026.07.017_bib1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/clc.4960171003","article-title":"Dyslipidemia and coronary-artery disease","volume":"17","author":"Kuo","year":"1994","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacl.2026.07.017_bib2","article-title":"The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: lower for longer is better","volume":"18","author":"Mhaimeed","year":"2024","journal-title":"Am J Prevent Cardiol"},{"issue":"36","key":"10.1016\/j.jacl.2026.07.017_bib3","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jacl.2026.07.017_bib4","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2026.07.017_bib5","first-page":"212","article-title":"Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER","volume":"2","author":"Karlson","year":"2016","journal-title":"Eur Heart J-Card Pha"},{"issue":"11","key":"10.1016\/j.jacl.2026.07.017_bib6","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"10.1016\/j.jacl.2026.07.017_bib7","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1592\/phco.23.14.1463.31942","article-title":"Ezetimibe: a selective cholesterol absorption inhibitor","volume":"23","author":"Nutescu","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"25","key":"10.1016\/j.jacl.2026.07.017_bib8","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"New Engl J Med"},{"issue":"29","key":"10.1016\/j.jacl.2026.07.017_bib9","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","article-title":"Low-density lipoprotein cholesterol targeting with pitavastatin 1 ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial","volume":"38","author":"Hagiwara","year":"2017","journal-title":"Eur Heart J"},{"issue":"10349","key":"10.1016\/j.jacl.2026.07.017_bib10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jacl.2026.07.017_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14740\/cr1224","article-title":"Effect of ezetimibe added to high-intensity statin therapy on low-density lipoprotein cholesterol levels: a meta-analysis","volume":"12","author":"Lee","year":"2021","journal-title":"Cardiol Res"},{"issue":"5","key":"10.1016\/j.jacl.2026.07.017_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00392-018-1379-z","article-title":"Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy","volume":"108","author":"Lorenzi","year":"2019","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"10.1016\/j.jacl.2026.07.017_bib13","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1177\/2047487318766612","article-title":"A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes","volume":"25","author":"Khan","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.07.017_bib14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.07.017_bib15","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Undertaking network meta-analyses","author":"Chaimani","year":"2022"},{"issue":"1","key":"10.1016\/j.jacl.2026.07.017_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2011.09.001","article-title":"Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease","volume":"59","author":"Uemura","year":"2012","journal-title":"J Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.07.017_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","article-title":"Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)","volume":"192","author":"McKenney","year":"2007","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.jacl.2026.07.017_bib18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4103\/2230-8210.111644","article-title":"Dyslipidemic drugs in metabolic syndrome","volume":"17","author":"Siddiqi","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jacl.2026.07.017_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10753-007-9041-3","article-title":"The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation","volume":"30","author":"Dagli","year":"2007","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/j.jacl.2026.07.017_bib20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s12013-014-9973-9","article-title":"Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients","volume":"70","author":"Lins","year":"2014","journal-title":"Cell Biochem Biophys"},{"issue":"11","key":"10.1016\/j.jacl.2026.07.017_bib21","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1253\/circj.CJ-17-0193","article-title":"Effect of ezetimibe on stabilization and regression of intracoronary plaque - the ZIPANGU study","volume":"81","author":"Ueda","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jacl.2026.07.017_bib22","first-page":"20","article-title":"Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)","volume":"9","author":"Bardini","year":"2010","journal-title":"Cardiovasc\u00a0Diabetol"},{"issue":"3","key":"10.1016\/j.jacl.2026.07.017_bib23","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2011.01.062","article-title":"Pleiotropic effects of ezetimibe\/simvastatin vs. high dose simvastatin","volume":"158","author":"Pesaro","year":"2012","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2026.07.017_bib24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1368-5031.2005.00565.x","article-title":"Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease","volume":"59","author":"Cruz-Fern\u00e1ndez","year":"2005","journal-title":"Int J Clin Pract"},{"issue":"14","key":"10.1016\/j.jacl.2026.07.017_bib25","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/eurheartj\/ehn166","article-title":"Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease","volume":"29","author":"Settergren","year":"2008","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.jacl.2026.07.017_bib26","doi-asserted-by":"crossref","first-page":"41582","DOI":"10.18632\/oncotarget.15078","article-title":"Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jacl.2026.07.017_bib27","first-page":"157","article-title":"No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance","volume":"101","author":"Maimstr\u00f6m","year":"2009","journal-title":"Thromb\u00a0Haemost"},{"issue":"7","key":"10.1016\/j.jacl.2026.07.017_bib28","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1253\/circj.CJ-13-0033","article-title":"Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: randomized controlled trial","volume":"77","author":"Matsue","year":"2013","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.jacl.2026.07.017_bib29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12872-019-1184-2","article-title":"Effects of ezetimibe\/simvastatin 10\/10\u2009mg versus Rosuvastatin 10\u2009mg on carotid atherosclerotic plaque inflammation","volume":"19","author":"Oh","year":"2019","journal-title":"BMC cardiovascular disorders"},{"issue":"3","key":"10.1016\/j.jacl.2026.07.017_bib30","first-page":"3","article-title":"LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD","volume":"7","author":"McKenney","year":"2005","journal-title":"MedGenMed"},{"issue":"24","key":"10.1016\/j.jacl.2026.07.017_bib31","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.2169\/internalmedicine.52.0731","article-title":"Effects of rosuvastatin vs. simvastatin\/ezetimibe on arterial wall stiffness in patients with coronary artery disease","volume":"52","author":"Liu","year":"2013","journal-title":"Intern Med"},{"issue":"12","key":"10.1016\/j.jacl.2026.07.017_bib32","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1368-5031.2005.00714.x","article-title":"Lipid-altering efficacy of switching from atorvastatin 10 mg\/day to ezetimibe\/simvastatin 10\/20 mg\/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease","volume":"59","author":"Barrios","year":"2005","journal-title":"Int J Clin Pract"},{"issue":"5","key":"10.1016\/j.jacl.2026.07.017_bib33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1074248413489771","article-title":"Increasing doses of simvastatin versus combined ezetimibe\/simvastatin: effect on circulating endothelial progenitor cells","volume":"18","author":"Pesaro","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.jacl.2026.07.017_bib34","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2006.10.064","article-title":"Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?","volume":"49","author":"Piorkowski","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacl.2026.07.017_bib35","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.amjcard.2008.09.076","article-title":"Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease","volume":"102","author":"Leiter","year":"2008","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2026.07.017_bib36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2796.2009.02128.x","article-title":"Lipid lowering versus pleiotropic effects of statins on skin microvascular function in patients with dysglycaemia and coronary artery disease","volume":"266","author":"Settergren","year":"2009","journal-title":"J Intern Med"},{"issue":"5","key":"10.1016\/j.jacl.2026.07.017_bib37","first-page":"467","article-title":"Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease","volume":"36","author":"Wang","year":"2017","journal-title":"Int\u00a0Angiol"},{"issue":"4","key":"10.1016\/j.jacl.2026.07.017_bib38","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1742-1241.2009.02022.x","article-title":"Lipid-altering efficacy of ezetimibe\/simvastatin 10\/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study","volume":"63","author":"Farnier","year":"2009","journal-title":"Int J Clin Pract"},{"issue":"5","key":"10.1016\/j.jacl.2026.07.017_bib39","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00059-008-3084-6","article-title":"Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets","volume":"33","author":"Liska","year":"2008","journal-title":"Herz"},{"issue":"1","key":"10.1016\/j.jacl.2026.07.017_bib40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2013.10.022","article-title":"Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: results of the GRAVITY randomized study","volume":"232","author":"Ballantyne","year":"2014","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.jacl.2026.07.017_bib41","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/eurheartj\/ehi881","article-title":"Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy","volume":"27","author":"Fichtlscherer","year":"2006","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2026.07.017_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2362.2009.02249.x","article-title":"Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events","volume":"40","author":"Stojakovic","year":"2010","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.jacl.2026.07.017_bib43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4070\/kcj.2011.41.3.149","article-title":"Comparison of ezetimibe\/simvastatin 10\/20 mg versus atorvastatin 20 mg in achieving a target low density lipoprotein-cholesterol goal for patients with very high risk","volume":"41","author":"Cho","year":"2011","journal-title":"Korean Circ J"},{"issue":"4","key":"10.1016\/j.jacl.2026.07.017_bib44","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1463-1326.2007.00725.x","article-title":"Efficacy of ezetimibe\/simvastatin 10\/20 and 10\/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus","volume":"9","author":"Constance","year":"2007","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.jacl.2026.07.017_bib45","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1177\/0091270009337011","article-title":"The VYtorin on carotid intima-media thickness and overall arterial rigidity (VYCTOR) study","volume":"49","author":"Meaney","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2026.07.017_bib46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1476-511X-9-80","article-title":"Ezetimibe\/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes","volume":"9","author":"Rotella","year":"2010","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.jacl.2026.07.017_bib47","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1253\/circj.CJ-11-0730","article-title":"Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study","volume":"76","author":"Kovarnik","year":"2012","journal-title":"Circ J"},{"issue":"10","key":"10.1016\/j.jacl.2026.07.017_bib48","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1253\/circj.CJ-11-0391","article-title":"Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy: from the viewpoint of cholesterol metabolism","volume":"75","author":"Okada","year":"2011","journal-title":"Circ J"},{"issue":"4","key":"10.1016\/j.jacl.2026.07.017_bib49","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1185\/030079907X182059","article-title":"Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease","volume":"23","author":"Blagden","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2026.07.017_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.amjcard.2021.05.039","article-title":"Effect of atorvastatin (10 mg) and ezetimibe (10 mg) combination compared to atorvastatin (40 mg) alone on coronary atherosclerosis","volume":"154","author":"Oh","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2026.07.017_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/2995602","article-title":"Ezetimibe improves rosuvastatin effects on inflammation and vascular endothelial function in acute coronary syndrome patients undergoing PCI","volume":"2021","author":"Sun","year":"2021","journal-title":"J Interv Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.07.017_bib52","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2174\/0118715257274373231211060714","article-title":"Efficacy of dyslipidemia control by combination therapy with rosuvastatin 10 mg and ezetimibe 10 mg compared with rosuvastatin 20 mg monotherapy in patients with chronic coronary syndromes: a randomized, single-blind controlled trial","volume":"22","author":"Tran","year":"2024","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"1","key":"10.1016\/j.jacl.2026.07.017_bib53","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13063-025-08817-7","article-title":"Comparison of ezetimibe and atorvastatin versus atorvastatin alone on short-term major adverse cardiac events after percutaneous coronary intervention, a double-blind placebo-controlled randomized clinical trial","volume":"26","author":"Farshidi","year":"2025","journal-title":"Trials"},{"issue":"8","key":"10.1016\/j.jacl.2026.07.017_bib54","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/eurjpc\/zwae049","article-title":"Small dense low-density lipoprotein cholesterol and coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis","volume":"31","author":"Rikhi","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"9753","key":"10.1016\/j.jacl.2026.07.017_bib55","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"42","key":"10.1016\/j.jacl.2026.07.017_bib56","volume":"43","author":"Visseren","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.jacl.2026.07.017_bib57","article-title":"Lipid-lowering efficacy of rosuvastatin","author":"Adams","year":"2014","journal-title":"Cochrane Db Syst Rev"},{"key":"10.1016\/j.jacl.2026.07.017_bib58","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2147\/DDDT.S332352","article-title":"Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: current insights","volume":"16","author":"Chilbert","year":"2022","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"10.1016\/j.jacl.2026.07.017_bib59","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2013.10.022","article-title":"Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: results of the GRAVITY randomized study","volume":"232","author":"Ballantyne","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.07.017_bib60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.amjcard.2021.11.041","article-title":"Very high\u00a0high-density lipoprotein cholesterol levels and cardiovascular mortality","volume":"167","author":"Liu","year":"2022","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.jacl.2026.07.017_bib61","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamacardio.2022.0912","article-title":"Association between high-density lipoprotein cholesterol levels and adverse cardiovascular outcomes in high-risk populations","volume":"7","author":"Liu","year":"2022","journal-title":"Jama Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.07.017_bib62","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1210\/clinem\/dgad406","article-title":"Does elevated high-density lipoprotein cholesterol protect against cardiovascular disease?","volume":"109","author":"Razavi","year":"2024","journal-title":"J Clin Endocr Metab"},{"key":"10.1016\/j.jacl.2026.07.017_bib63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2016.03.016","article-title":"Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: a systematic review and meta-analysis","volume":"248","author":"Peters","year":"2016","journal-title":"Atherosclerosis"},{"issue":"25","key":"10.1016\/j.jacl.2026.07.017_bib64","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.017_bib65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cca.2017.05.006","article-title":"Meta-analysis of serum non-high-density lipoprotein cholesterol and risk of coronary heart disease in the general population","volume":"471","author":"Liu","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jacl.2026.07.017_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2018.11.002","article-title":"Non-high-density lipoprotein cholesterol and risk of cardiovascular disease in the general population and patients with type 2 diabetes: a systematic review and meta-analysis","volume":"147","author":"Cao","year":"2019","journal-title":"Diabetes Res Clin Pr"},{"issue":"12","key":"10.1016\/j.jacl.2026.07.017_bib67","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL-C cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"Jama-J Am Med Assoc"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:20:16Z","timestamp":1793708416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426004484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1933287426004484"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.07.017","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of different statin intensities combined with ezetimibe on lipid profile improvement in patients with coronary heart disease: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}